ME NewsWire/ Business Wire
SAN DIEGO. - Thursday, September 11th 2014
Pathway Genomics Corporation, a San Diego-based CLIA and CAP accredited clinical laboratory that offers genetic testing services globally, today announced it has launched BreastTrueTM High Risk Panel, a blood or saliva next-generation sequencing test with deletion/duplication analysis to detect mutations in seven high-risk breast cancer susceptibility genes, including BRCA1, BRCA2 and PALB2.
Recent studies of breast cancer survivors have shown that approximately 70 percent of the mutations identified were BRCA1/2 mutations. Approximately 4 percent had germline mutations in other cancer-susceptibility genes, including high-risk genes. These additional high-risk genes include CDH1, PALB2, PTEN, STK11, and TP53. Pathway Genomics’BreastTrue High Risk Panel analyzes all of these genes.
“The development and launch of this breast cancer high risk panel is a necessity to effecti
...
Read more »